At ECR 2026, Avandra’s Ryan Tarzy observed a clear shift in the clinical AI landscape: developers are moving beyond raw data volume and prioritizing curated, high-quality datasets that can support real-world clinical deployment. This recap highlights key industry insights and a joint case study with Harrison.ai.

As drug development accelerates, regulators are increasingly prioritizing evidence that stays close to the patient and can move faster—making imaging data, which captures disease directly and supports earlier, more meaningful signals, an increasingly valuable part of regulatory decision-making.

Most RWD studies rely on EHR and claims, but without imaging they miss the essential clinical truth that makes real-world evidence precise, validated, and trustworthy.